Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018204690) DIAGNOSIS AND TREATMENT OF INFECTION INVOLVING KILLER T FOLLICULAR HELPER CELLS, METHODS OF PREPARATION, AND USES THEREOF
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/204690 International Application No.: PCT/US2018/030948
Publication Date: 08.11.2018 International Filing Date: 03.05.2018
IPC:
G01N 1/28 (2006.01) ,G01N 33/563 (2006.01) ,G01N 33/564 (2006.01) ,G01N 33/569 (2006.01) ,G01N 33/96 (2006.01) ,C12N 5/0783 (2010.01) ,A61P 31/04 (2006.01) ,A61P 37/00 (2006.01)
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
1
Sampling; Preparing specimens for investigation
28
Preparing specimens for investigation
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53
Immunoassay; Biospecific binding assay; Materials therefor
563
involving antibody fragments
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53
Immunoassay; Biospecific binding assay; Materials therefor
564
for pre-existing immune complex or autoimmune disease
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53
Immunoassay; Biospecific binding assay; Materials therefor
569
for micro-organisms, e.g. protozoa, bacteria, viruses
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
96
involving blood or serum control standard
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5
Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07
Animal cells or tissues
071
Vertebrate cells or tissues, e.g. human cells or tissues
078
Cells from blood or from the immune system
0783
T cells; NK cells; Progenitors of T or NK cells
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
04
Antibacterial agents
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37
Drugs for immunological or allergic disorders
Applicants:
LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY [US/US]; 9420 Athena Circle LA JOLLA, California 92037, US
Inventors:
CROTTY, Shane; US
DAN, Jennifer; US
Agent:
PAPPAS, Stephen; US
Priority Data:
62/500,49903.05.2017US
Title (EN) DIAGNOSIS AND TREATMENT OF INFECTION INVOLVING KILLER T FOLLICULAR HELPER CELLS, METHODS OF PREPARATION, AND USES THEREOF
(FR) DIAGNOSTIC ET TRAITEMENT D'UNE INFECTION IMPLIQUANT DES CELLULES T FOLLICULAIRES TUEUSES AUXILIAIRES, LEURS PROCÉDÉS DE PRÉPARATION ET UTILISATIONS
Abstract:
(EN) Recurrent tonsillitis disease (RT) is a common indication for pediatric tonsillectomy, the most frequent childhood surgery. It is unknown why some children develop RT. The present disclosure demonstrates that RT tonsils exhibit significantly smaller germinal centers than non-RT tonsils, concomitant with a bias against Group A Streptococcus (GAS) -specific germinal center follicular helper CD4+ T cells (GC Tfh), and significantly reduced antibodies to the GAS virulence factor SpeA. The present disclosure also shows a significant immunogenetic component to this disease, with the identification of 'at risk' and 'protective' HLA alleles for RT. Finally, the present disclosure identifies a new cell type, granzyme B+ GC Tfh cells, which are activated by SpeA, are significantly more abundant in RT GC Tfh cells, and have the capacity to kill B cells, thus, providing a window into the immunology and genetics of a classic childhood disease and identifies a new type of pathogenic T cell.
(FR) L'amygdalite récurrente (RT) est une indication courante pour une amygdalectomie pédiatrique, la chirurgie infantile la plus fréquente. On ignore pourquoi certains enfants développent une RT. La présente divulgation démontre que les amygdales RT ont des centres germinatifs significativement plus petits que les amygdales non-RT, et présentent concurremment une discrimination à l'encontre des cellules T folliculaires CD4+ auxiliaires des centres germinatifs (CG Tfh) spécifiques des Streptococci du Groupe A (GAS), et des anticorps anti-facteur de virulence GAS, SpeA, significativement réduits. La présente divulgation montre également un composant immunogénétique significatif vis-à-vis de cette maladie, avec l'identification d'allèles HLA "de risque" et "protecteurs" envers la RT. Pour finir, la présente divulgation identifie un nouveau type de cellules, dites cellules granzymse B + CG Tfh, qui sont activées par SpeA, sont significativement plus abondantes dans les cellules RT CG Tfh, et ont la capacité de détruire les cellules B, ouvrant ainsi une fenêtre dans l'immunologie et la génétique d'une maladie infantile classique et identifiant un nouveau type de lymphocte T pathogène.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)